Cargando…
The challenge of developing universal vaccines
Antigenic variability of immunodominant antigens is a common mechanism used by pathogens to escape the immune response. Frequently, the proposed solution is a universal vaccine based on conserved antigens present on all strains of the pathogen. Indeed, a lot of progress has been made in the developm...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155208/ https://www.ncbi.nlm.nih.gov/pubmed/21904572 http://dx.doi.org/10.3410/M3-16 |
_version_ | 1782210093145653248 |
---|---|
author | Rappuoli, Rino |
author_facet | Rappuoli, Rino |
author_sort | Rappuoli, Rino |
collection | PubMed |
description | Antigenic variability of immunodominant antigens is a common mechanism used by pathogens to escape the immune response. Frequently, the proposed solution is a universal vaccine based on conserved antigens present on all strains of the pathogen. Indeed, a lot of progress has been made in the development of vaccines that induce broad immune responses. However, truly universal vaccines are not easy to produce and still face many challenges, mostly because in those pathogens that use antigenic variability to escape the immune response, conserved antigens have been selected by evolution to be poorly immunogenic. This review describes the progress made towards the development of vaccines inducing broad protection against Neisseria meningitidis, influenza, HIV, and Candida and the challenges of developing truly universal vaccines. |
format | Online Article Text |
id | pubmed-3155208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Faculty of 1000 Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31552082011-09-08 The challenge of developing universal vaccines Rappuoli, Rino F1000 Med Rep Review Article Antigenic variability of immunodominant antigens is a common mechanism used by pathogens to escape the immune response. Frequently, the proposed solution is a universal vaccine based on conserved antigens present on all strains of the pathogen. Indeed, a lot of progress has been made in the development of vaccines that induce broad immune responses. However, truly universal vaccines are not easy to produce and still face many challenges, mostly because in those pathogens that use antigenic variability to escape the immune response, conserved antigens have been selected by evolution to be poorly immunogenic. This review describes the progress made towards the development of vaccines inducing broad protection against Neisseria meningitidis, influenza, HIV, and Candida and the challenges of developing truly universal vaccines. Faculty of 1000 Ltd 2011-08-01 /pmc/articles/PMC3155208/ /pubmed/21904572 http://dx.doi.org/10.3410/M3-16 Text en © 2011 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
spellingShingle | Review Article Rappuoli, Rino The challenge of developing universal vaccines |
title | The challenge of developing universal vaccines |
title_full | The challenge of developing universal vaccines |
title_fullStr | The challenge of developing universal vaccines |
title_full_unstemmed | The challenge of developing universal vaccines |
title_short | The challenge of developing universal vaccines |
title_sort | challenge of developing universal vaccines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155208/ https://www.ncbi.nlm.nih.gov/pubmed/21904572 http://dx.doi.org/10.3410/M3-16 |
work_keys_str_mv | AT rappuolirino thechallengeofdevelopinguniversalvaccines AT rappuolirino challengeofdevelopinguniversalvaccines |